Search
Apazunersen
go.drugbank.com/drugs/DB16981InvestigationalIt is being investigated for the treatment of Angelman Syndrome.[L46772]
SAR421869
go.drugbank.com/drugs/DB17909InvestigationalSAR421869 is a Lentiviral Vector Containing The Human My07A Gene currently being investigated for the treatment of retinitis pigmentosa associated with Usher syndrome 1B gene defect.
GS-9191
go.drugbank.com/drugs/DB15084InvestigationalGS-9191 is under investigation in clinical trial NCT00499967 (Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts).
Mesosulfuron-methyl
go.drugbank.com/drugs/DB15184ExperimentalMesosulfuron-methyl is under investigation in clinical trial NCT01118117 (A Multi-center Clinical Trial of the Misago™ Self-Expanding Stent System for Superficial Femoral Artery).
PL-3994
go.drugbank.com/drugs/DB15355InvestigationalPL-3994 is under investigation in clinical trial NCT01304628 (Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma).
Iseganan
go.drugbank.com/drugs/DB16010InvestigationalIseganan is under investigation in clinical trial NCT00022373 (Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer).
Zolimidine
go.drugbank.com/drugs/DB13593ExperimentalCategories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)Moroxydine
go.drugbank.com/drugs/DB13597ExperimentalCategories: Antivirals for Systemic Use, Antiinfectives for Systemic UseTPMPA
go.drugbank.com/drugs/DB16754Experimental[A245308,A245313] TPMPA is used as a pharmacological probe for the investigation of GABA<sub>C</sub> receptor function.[A245313] … TPMPA ((1,2,5,6-tetrahydropyridine-4-yl)methylphosphinic acid) is a selective antagonist of GABA<sub>C</sub> receptors (also known as GABA-ρ or GABA<sub>A-ρ</sub> receptors).
Benfluorex
go.drugbank.com/drugs/DB09022ApprovedWithdrawnIt was patented and manufactured by a French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.